Qvr LLC Abb Vie Inc. Call Options Transaction History

Qvr LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 10, 2023	SELL	$138.31 - $165.87 $5.24 Million - $6.29 Million	-37,900 Reduced 93.12%	2,800 $452,000
Q3 2022 Oct 25, 2022	BUY	$134.21 - $153.93 $2.19 Million - $2.51 Million	16,300 Added 66.8%	40,700 $5.46 Million
Q2 2022 Aug 01, 2022	SELL	$137.62 - $174.96 $5.39 Million - $6.86 Million	-39,200 Reduced 61.64%	24,400 $3.74 Million
Q1 2022 Apr 27, 2022	BUY	$131.98 - $163.75 $8.39 Million - $10.4 Million	63,600 New	63,600 $10.3 Million
Q4 2021 Jan 31, 2022	SELL	$107.43 - $135.93 $1.82 Million - $2.3 Million	-16,900 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$106.4 - $120.78 $744,800 - $845,460	7,000 Added 70.71%	16,900 $1.82 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $652,302 - $726,702	6,200 Added 167.57%	9,900 $1.12 Million
Q1 2021 May 03, 2021	BUY	$102.3 - $112.62 $317,130 - $349,122	3,100 Added 516.67%	3,700 $400,000
Q4 2020 Jan 29, 2021	BUY	$80.49 - $108.67 $48,294 - $65,202	600 New	600 $64,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Qvr LLC, based on Form 13F filings with the SEC.

Stay updated on Qvr LLC with notifications on news.